Last reviewed · How we verify
Shuxuetong Injection
Shuxuetong Injection, marketed by Beijing Tiantan Hospital, is a therapeutic drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the hospital's reputation and expertise. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Shuxuetong Injection |
|---|---|
| Also known as | Shuxuetong |
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
- Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke (PHASE4)
- Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism (PHASE4)
- A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shuxuetong Injection CI brief — competitive landscape report
- Shuxuetong Injection updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI